Sodium-Glucose Cotransporter-2 Inhibitor versus Beta-Blocker Use for Hepatocellular Carcinoma Risk among People with Hepatitis B or C Virus Infection and Diabetes Mellitus

SIMPLE SUMMARY: The authors used a large Taiwanese database of patients with chronic hepatitis B or C in order to study if SGLT2I, as compared to BB, may decrease HCC. In brief, SGLT2I caused a risk reduction in the likelihood of HCC development of about 73%. ABSTRACT: Objective: The current study d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wei-Syun, Lin, Cheng-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093089/
https://www.ncbi.nlm.nih.gov/pubmed/37046765
http://dx.doi.org/10.3390/cancers15072104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093089/
https://www.ncbi.nlm.nih.gov/pubmed/37046765
http://dx.doi.org/10.3390/cancers15072104

Ejemplares similares